Biosensors International
Encyclopedia
Biosensors International Group (SGX: B20) is a company that specializes in developing, manufacturing and marketing innovative medical devices for use in interventional cardiology and critical care procedures. The company was established in 1990 and was listed on the Singapore Stock Exchange (SGX) in May 2005. The global headquarters of the company are based in Morges, Switzerland, with the main R&D and manufacturing base located in Singapore.
With the increasing use of the BioMatrix™ family of drug-eluting stents, the company is rapidly emerging as a leader in the global coronary stent market. The forthcoming launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce this market position.
All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer‐free stent abluminally coated with BA9, is currently undergoing clinical evaluation.
The Biosensors interventional cardiology product range is completed by the Gazelle™ bare-metal stent system and the Powerline™ PTCA balloon dilatation catheter.
Biosensors’ Critical Care Products division develops and markets vascular catheters, pressure monitoring kits, arterial blood sampling kits and blood pressure transducers for use in open-heart surgery and critical care areas of the hospital.
Biosensors owns a 50% stake in JW Medical Systems (JWMS), one of China’s leading manufacturer and supplier of drug-eluting stents, with whom they share common technology. The Company is currently in the process of acquiring the remaining 50%, which will make JWMS a wholly owned subsidiary of Biosensors.
Biosensors has licensed both BA9 and their biodegradable polymer technology to the Terumo Corporation, one of Japan’s leading medical device companies. Terumo has incorporated this proprietary coating into their Nobori™ DES. Terumo has an exclusive licence to this technology in Japan, and is permitted to co-market Nobori in all other countries globally with the exception of the US.
For further information about Biosensors, please visit: www.biosensors.com
With the increasing use of the BioMatrix™ family of drug-eluting stents, the company is rapidly emerging as a leader in the global coronary stent market. The forthcoming launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce this market position.
All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer‐free stent abluminally coated with BA9, is currently undergoing clinical evaluation.
The Biosensors interventional cardiology product range is completed by the Gazelle™ bare-metal stent system and the Powerline™ PTCA balloon dilatation catheter.
Biosensors’ Critical Care Products division develops and markets vascular catheters, pressure monitoring kits, arterial blood sampling kits and blood pressure transducers for use in open-heart surgery and critical care areas of the hospital.
Biosensors owns a 50% stake in JW Medical Systems (JWMS), one of China’s leading manufacturer and supplier of drug-eluting stents, with whom they share common technology. The Company is currently in the process of acquiring the remaining 50%, which will make JWMS a wholly owned subsidiary of Biosensors.
Biosensors has licensed both BA9 and their biodegradable polymer technology to the Terumo Corporation, one of Japan’s leading medical device companies. Terumo has incorporated this proprietary coating into their Nobori™ DES. Terumo has an exclusive licence to this technology in Japan, and is permitted to co-market Nobori in all other countries globally with the exception of the US.
For further information about Biosensors, please visit: www.biosensors.com